Prostate Cancer : Episode 4

Video

Episode 4 - Treatment Guidelines and Economic Considerations

During this segment, Raoul S. Concepcion, MD, explains how the rapid development of agents for castration-resistant prostate cancer (CRPC) has led to an expanding number of clinical guidelines, developed by multiple organizations, for clinicians’ use during important treatment-decisions.

However, he explains that the treatment options recommended in these guidelines are expensive, creating a challenge to both clinicians and payers.

To clarify misconceptions about medical policy and coverage for patients with CRPC, Michael Kolodziej, MD, discusses the variables that payers consider when making decisions about coverage for these expensive treatment options.


Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Screenshot of a webinar panel discussion with Viet Le, PA-C; Nathan Wong, PhD, MPH; Alison Bailey, MD; and Martha Gulati, MD, MS
Mehmet Oz, MD, MBA
Ayodeji Adegunsoye, MD, PhD, MSc
Marilyn Glassberg, MD
Dr Caroline Vovan
Interview with Miriam Freimer, MD, The Ohio State University Wexner Medical Center
Merrill H. Stewart, MD
Rachel Rohaidy, MD
Mansi Shah, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo